PROLONGing remissions in patients with CLL
Mené sur 474 patients atteints d'une leucémie lymphocytaire chronique récidivante, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ofatumumab en traitement d'entretien (durée médiane de suivi : 19,1 mois)
Chronic lymphocytic leukaemia is a malignancy of mature CD20-expressing B cells that belongs to the indolent class of non-Hodgkin lymphomas. Similar to other B-cell lymphomas, the use of anti-CD20 antibodies in combination with chemotherapy, referred to as chemoimmunotherapy, has become standard treatment and can improve overall survival compared with chemotherapy alone. However, most patients are not cured by chemoimmunotherapy, and relapse commonly occurs within a few years of completing treatment.
The Lancet Oncology , commentaire, 2014